

BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: bpgoffice@wignet.com http://www.wignet.com

Name of Journal: World Journal of Transplantation

ESPS Manuscript NO: 22007

Manuscript type: Minireviews

COMMENTS TO AUTHORS

This is an interesting mini-review on a topic increasingly popular and clinically relevant in solid organ transplantation. The review is, in general, well written, although there are some stylistic issues which should be addressed. Pending issues are adequately underlined as well as the challenges to be faced for clinical translation of current knowledge in the field. Main questions related to the topic are well addressed in a concise manner, probably too concise. For example, p values for comparison data in each cited study are not necessary. There are several minor points that the authors should elaborate. 1/ The first sentence in the Introduction section, starting with "Tacrolimus is an ... in combination with ..." is too definitive. Three are many ways for combination therapies in kidney transplant recipients depending on transplant programs. Induction therapy can be thymoglobulin or alemtuzumab or others. Please re-write the first sentence. 2/ In Abstract, there is no need for abbreviation MMF as MMF is only used once in the abstract. CF should be spelled out (cystic fibrosis) in the abstract. 3/ The authors used so many unnecessary abbreviations in the main text. Those should be simply spelled out without abbreviation when used only once. Examples include but no limited to: IL-2 in page 3, CYP3A in page 3, PRA in page 8, CIT in page 8, DGF in page 8, CrCl in page 8, FSGS in page 9, MDRD4 in page 12, ELTR in page 12, MPR in page 20, BNF in page 20, and NHS in page 20. 4/ Miss spelling in the title. "Transplantion" should be "transplantation".

Response to reviewer: Thank you for the comments. We have made the changes above. We have re-written the first sentence. We have gone through and eliminated abbreviations that are not used again.

COMMENTS TO AUTHORS

I think it is better to make a systematic review instead of a mini review on this important topic, and meta-analysis if applicable. Moreover, the study has not been prepared well. For example in the first sentence of the abstract, while you were talking about what tacrolimus is, you've brought manufacturer's data which doesn't make any sense. Some English revision seem also needed (e.g. "It is not recommended in the use of liver transplant patient's due to the increased risk of mortality in female recipients.")

Response to reviewer: At this time we do not feel a systemic review is needed. There is still minimal



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

data available. In the future with more literature a meta-analysis or systemic review may be applicable. We have gone through the manuscript and made grammatical and English revisions. Thank you for your comments.

COMMENTS TO AUTHORS

This manuscript reviews extended release tacrolimus in solid organ transplantation. It is well written, and acceptable for World Journal of transplantation except one. Please mention the role of extended release tacrolimus in other solid organ transplantation (pancreas, small intestine, multiple organ transplantation)

Response to reviewer: Thank you for your comments. We have added a statement in the conclusion regarding the use of Astagraf in multiple organ transplantation, pancreas and small intestine.